A single centre, double-blind, randomized, 2-way crossover study to investigate the effect of up-titration regimen of ponesimod on cardiovascular safety and tolerability

Trial Profile

A single centre, double-blind, randomized, 2-way crossover study to investigate the effect of up-titration regimen of ponesimod on cardiovascular safety and tolerability

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs Ponesimod (Primary)
  • Indications Graft-versus-host disease; Immunological disorders; Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 05 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top